KPTI · Karyopharm Therapeutics Inc. · Share Buybacks
$0.67
-0.14 (-16.99%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$36.74M
Shares
22.68M
Volume · Oct 5
954.48K
Avg daily vol (3M)
1.66M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-02-17 | — | $100,000,000 | $100,000,000 as of 2025-09-30 | — | 10-Q , filed 2025-11-03 |